Program at a Glance

Click on each day to access the program.

LEGEND: Basic Science Clinical Science Public Health

* program subject to change without notice.

 

7:00AM
2:00PM
2:15PM
3:45PM
4:00PM
4:15PM
Thursday, June 14
CAHN Symposium 7:00AM‑3:30PM 7:00AM - 8:00AM Breakfast & Welcome
Donna Zukowski - Welcome

8:00AM - 10:00AM: SESSION I: CLINICAL PEARLS - MODERATOR: KATHY POLDRE
David Wong - Clinical pearls and perils in managing patients with chronic liver disease
Giada Sebastiani- Pitfalls of non-invasive fibrosis markers
Norah Terrault -Real world experience of hepatitis B
Q & A period | Refreshment Break

10:00AM - 12:30PM: SESSION II: PRACTICE AND RESEARCH - MODERATOR: CHERYL DALE
Michelle Clayton - Best nursing practices in managing alcohol related liver disease (ARLD)
HoChong Gilles - New trends in managing non-alcoholic fatty liver disease (NAFLD)
Oral Abstract 1
Oral Abstract 2
Q & A period | Lunch

12:30PM - 2:15PM: SESSION III: EVOLUTION AND INNOVATION - MODERATOR: COLINA YIM
Lisa Douglas - Advance nursing practice role in HCC management
Saroj Nazareth - Nursing initiatives in Australia since the HCV DAA era
Morris Sherman - Future direction of Hepatology
Q & A period | Refreshment Break

2:15PM - 3:30PM: SESSION IV:  PANEL DISCUSSION - MODERATOR: LESLEY GALLAGHER
Michelle Clayton, Sally Spruce, HoChong Gilles, Donna Zukowski - Hepatology Nursing – New directions, New challenges, New opportunities?
Kathy Poldre, Colina Yim, Cheryl Dale - Closing Remarks and Evaluation
Registration 7:00AM‑2:00PM Welcome WHO Elimination Targets Gottfried Hirnshchall - Elmination targets: Rationale and WHO's role in helping countries get there

David Thomas - What tools are needed to generate the evidence - measuring success

Greg Dore - National elimination in a focused epidemic: Australia

Manal El-Sayed - National elimination in a generalized epidemic: Egypt
Afternoon Break 3:45PM‑4:15PM Exhibits & Posters 4:30PM‑8:00PM HCV Virology Thomas Baumert - HCV infection and entry

Jane McKeating - Physiological Regulation of HCV Replication

Ralf Bartenschlager - HCV virion production and assembly

Oral Abstracts
New Biomarkers & Endpoints in HBV Henry Chan - The value of HBsAg quantification in the natural history and treatment of HBV

Jean Michel Pawlotsky - Choosing the right endpoint for HBV treatment

Harry Janssen - New Biomarkers for HBV infection

Oral Abstracts
HEV Pathogenesis & Treatment Shiv Sarin - HEV and emerging worldwide pathogen?

Heiner Wedemeyer - Treatment of HEV infection

TBD - HEV in immunocompromised patients

Oral Abstracts
Pan American Symposium